Table 5. In Vitro Susceptibility Rates of different pathogens to empiric initial intraperitoneal therapies in period 2 (1993–2003).
| 1993–2003 | Cefazolin n (% susceptible) | Ceftazidim n (% susceptible) | Gentamicin n (% susceptible) | Vancomycin n (% susceptible) |
|---|---|---|---|---|
| Gram-positive organisms | 81 (75) | 4 (25) | 73 (58) | 81 (99) a |
| Staphylococcus aureus | 11 (91) | NT | 11 (91) | 11 (100) |
| MSSA | 11 (91) | NT | 11 (91) | 11 (100) |
| MRSA | NA | NA | NA | NA |
| CNS | 35 (63) | NT | 35 (60) | 35 (100) |
| MRSE | NT | NT | 9 (67) | 9 (100) |
| Enterococcus spp. | NT | NT | 8 (63) | 8 (88) a |
| Streptococcus spp. | 22 (91) | NT | 15 (20) | 23 (100) |
| Other gram positive rods | 3 (67) | 2 (0) | 3 (67) | 3 (100) |
| Others | 1 (0) | NT | 1 (0) | 1(100) |
| Gram-negative organisms | NT | 38 (84) | 38 (82) | NT |
| Pseudomonas spp. | NT | 8 (75) | 8 (100) | NT |
| Stenotrophomonas spp. | NT | 1 (0) | 1 (0) | NT |
| Escherichia coli | NT | 11 (100) | 11 (82) | NT |
| Klebsiella spp. | NT | 2 (100) | 2 (50) | NT |
| Acinetobacter spp. | NT | 4 (25) | 3 (75) | NT |
| Others | NT | 12 (100) b | 12 (83) b | NT |
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; CNS, coagulase-negative staphylococci; MRSE, methicillin-resistant Staphylococcus epidermidis; NA, not available; NT, not tested;
a one vancomycin resistant enterococcus (VRE);
b Bacteroides spp.; variables are expressed in number of antibiograms (percentage in parentheses regarding Susceptibility Rate);